DAPA VILDA 10/100 SR

Dapa Vilda 10/100 SR is a rational fixed-dose combination (FDC) designed for the management of Type 2 Diabetes Mellitus in adult patients who require more comprehensive glycemic control than a single antidiabetic agent can provide. It brings together two distinct, well-established drug classes — an SGLT2 inhibitor and a DPP-4 inhibitor — into a single once-daily sustained-release tablet, simplifying treatment while addressing multiple underlying mechanisms of hyperglycemia.

Manufactured by Steris Healthcare, this combination is prescribed by physicians, endocrinologists, and diabetologists across India as part of the growing shift toward multi-mechanism, patient-friendly diabetes therapy that reduces daily pill burden without compromising efficacy.

Product Information

Why It's Important

Type 2 Diabetes Mellitus is one of India's most significant public health challenges, with the country home to one of the largest diabetic populations globally. A large proportion of patients fail to achieve adequate glycemic targets on monotherapy alone, and treatment intensification is frequently required — yet many patients struggle with the complexity and pill burden of managing multiple separate medications.

This is precisely why combination therapies like Dapa Vilda 10/100 SR hold significant clinical importance. By combining Dapagliflozin and Vildagliptin into a single sustained-release tablet, this formulation addresses two separate but complementary pathways of glucose dysregulation simultaneously: Dapagliflozin works independently of insulin by promoting glucose excretion through the kidneys, while Vildagliptin enhances the body's own incretin-based insulin response in a glucose-dependent manner. This dual mechanism allows for more comprehensive glycemic control while maintaining a relatively low risk of hypoglycemia compared to older combination regimens involving sulfonylureas.

Beyond glucose control, SGLT2 inhibitors like Dapagliflozin have demonstrated additional cardiovascular and renal protective benefits in landmark clinical outcome trials, making this combination particularly relevant for the many Indian diabetic patients who also carry elevated cardiovascular and chronic kidney disease risk. Simplifying complex multi-drug regimens into a single tablet also meaningfully improves medication adherence — a critical factor in achieving sustained long-term glycemic control and reducing the risk of diabetes-related complications such as neuropathy, retinopathy, and nephropathy.

Key Benefits 

What Are the Benefits of Dapa Vilda 10/100 SR?

Dapagliflozin 10mg + Vildagliptin SR 100mg, as formulated in Dapa Vilda 10/100 SR, offers several clinically meaningful advantages:

• Dual, complementary mechanism of action: Combining an SGLT2 inhibitor with a DPP-4 inhibitor addresses glucose control through two independent pathways, often achieving greater HbA1c reduction than either drug alone.
• Low hypoglycemia risk: Both Dapagliflozin and Vildagliptin work through glucose-dependent or insulin-independent mechanisms, resulting in a comparatively low risk of hypoglycemia compared to sulfonylurea-based regimens.
• Modest weight reduction: Dapagliflozin promotes glucose and calorie loss through urine, which is often associated with modest weight reduction — a valuable secondary benefit for overweight Type 2 diabetic patients.
• Cardiovascular and renal benefit potential: SGLT2 inhibitors like Dapagliflozin have shown benefits in reducing heart failure hospitalization and slowing progression of chronic kidney disease in various patient populations, making this combination clinically relevant beyond glucose control alone.
• Simplified once-daily dosing: The sustained-release formulation of Vildagliptin combined with Dapagliflozin allows for convenient once-daily administration, improving adherence compared to multiple separate tablets.
• Blood pressure benefit: Dapagliflozin has a mild diuretic-like effect that can contribute to modest reductions in blood pressure, offering an additional benefit for many Type 2 diabetic patients who also have hypertension.
• Established combination rationale: Both drug classes are widely used and well-studied individually, giving physicians a strong evidence base for combining them in appropriate patients.
• Trusted manufacturing standards: Dapa Vilda 10/100 SR is manufactured by Steris Healthcare, a WHO-GMP and ISO 9001:2018 certified pharmaceutical company, ensuring consistent potency, sustained-release performance, and batch-to-batch reliability.

Side Effects 

Because this is a combination product, side effects may arise from either or both components. Commonly reported side effects include:

• Urinary tract infections, due to increased glucose concentration in urine from Dapagliflozin
• Genital fungal infections (such as vaginal or penile yeast infections), also related to glucosuria
• Increased urination frequency
• Mild dizziness, particularly related to fluid shifts in the early weeks of treatment
• Headache
• Nausea
• Nasopharyngitis (common cold-like symptoms)
• Mild joint pain

Most of these effects are mild to moderate and tend to be manageable with adequate hydration, genital hygiene practices, and, where needed, dose or regimen adjustment by the prescribing physician.

Precautions & Warnings

Before starting Dapa Vilda 10/100 SR, patients and prescribers should consider the following precautions:

• Renal Impairment: Dapagliflozin's glucose-lowering efficacy decreases with declining kidney function, and use should be carefully assessed in patients with moderate to severe renal impairment.
• Volume Depletion: Patients who are elderly, on diuretics, or have low blood pressure should be monitored for signs of dehydration or hypotension, particularly during treatment initiation.
• Genital and Urinary Infections: Patients should be counseled on genital hygiene practices to reduce the risk of fungal and urinary tract infections associated with glucosuria.
• Diabetic Ketoacidosis Risk: Patients should be aware of the signs of ketoacidosis and should temporarily discontinue therapy and seek medical advice during acute illness, surgery, or significantly reduced food/fluid intake ("sick day rules").
• Pancreatitis History: Vildagliptin should be used cautiously in patients with a history of pancreatitis.
• Liver Function: Periodic liver function monitoring may be advised, particularly in patients with pre-existing hepatic conditions.
• Pregnancy and Lactation: This combination is generally not recommended during pregnancy or breastfeeding; alternative diabetes management should be discussed with the treating physician.
• Bladder Cancer History: Caution is advised in patients with a history of bladder cancer, and this should be discussed with the prescribing physician.
• Drug Interactions: Caution is required when combining with diuretics, other antihyperglycemic agents, and certain medications affecting renal function, due to potential additive effects.

Mechanism of Action 

Dapa Vilda 10/100 SR works through two independent, complementary mechanisms:

Dapagliflozin (SGLT2 Inhibitor):

1. Inhibition of Renal Glucose Reabsorption: Dapagliflozin selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule, which is responsible for the majority of glucose reabsorption from the kidney's filtrate.
2. Increased Urinary Glucose Excretion: By blocking SGLT2, Dapagliflozin causes excess glucose to be excreted in urine rather than reabsorbed into the bloodstream, lowering blood glucose levels independent of insulin secretion or action.
3. Additional Metabolic Effects: This glucose excretion is accompanied by modest calorie loss, contributing to weight reduction, along with mild osmotic diuresis that can modestly lower blood pressure.

Vildagliptin SR (DPP-4 Inhibitor):

1. Inhibition of Dipeptidyl Peptidase-4 (DPP-4) Enzyme: Vildagliptin blocks the DPP-4 enzyme responsible for rapidly breaking down incretin hormones, particularly GLP-1 and GIP.
2. Enhanced Incretin Activity: By preserving active incretin hormone levels, Vildagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon secretion from alpha cells.
3. Glucose-Dependent Action: Because Vildagliptin's insulin-stimulating effect is glucose-dependent, it carries a low intrinsic risk of causing hypoglycemia on its own.

Frequently Asked Questions (FAQ)

1. Where can I buy Dapagliflozin Vildagliptin online?
You can purchase Dapagliflozin Vildagliptin through licensed online pharmacies or authorized pharmaceutical suppliers. Check the strength, manufacturer, batch number, expiry date, and packaging before purchasing.

2. What is the price of Dapagliflozin Vildagliptin?
The price may vary depending on the brand, strength, pack size, manufacturer, seller, and applicable pharmacy charges. Check the current listed price before placing an order.

3. Can I order Dapagliflozin Vildagliptin online?
Yes, Dapagliflozin Vildagliptin can be ordered online where legally available. Since it is a prescription diabetes medicine, a valid prescription may be required.

4. Is Dapagliflozin Vildagliptin available from Steris Healthcare?
Availability depends on Steris Healthcare's current product range and stock status. Contact Steris Healthcare or an authorized distributor to confirm availability, strength, pack size, and ordering details.

5. What is Dapagliflozin Vildagliptin used for?
Dapagliflozin Vildagliptin is used to help control blood glucose levels in adults with type 2 diabetes mellitus, along with appropriate diet and exercise. The combination works through two different mechanisms to improve blood sugar control.

6. What is the composition of Dapagliflozin Vildagliptin?
Dapagliflozin Vildagliptin contains Dapagliflozin and Vildagliptin as active ingredients. The exact strength and inactive ingredients depend on the specific formulation.

7. Is a prescription required?
Yes, Dapagliflozin Vildagliptin should be used under the supervision of a qualified healthcare professional, and a prescription is generally required. The appropriate dose depends on the patient's condition and other diabetes medicines being used.

8. How should Dapagliflozin Vildagliptin be taken?
Take Dapagliflozin Vildagliptin exactly as prescribed by your doctor. Swallow the tablet with water and follow the recommended schedule. Do not change the dose or stop treatment without medical advice.

9. What should I know before buying Dapagliflozin Vildagliptin?
Before buying, verify the exact strength, composition, manufacturer, batch number, expiry date, packaging, and storage instructions. Inform your doctor about kidney or liver problems, dehydration, urinary or genital infections, pregnancy or breastfeeding, and all medicines you are taking.

10. How can I order Dapagliflozin Vildagliptin online?
Order Dapagliflozin Vildagliptin through a licensed online pharmacy or authorized pharmaceutical supplier. Provide a valid prescription if required, select the prescribed strength and pack size, and verify the product and delivery details before completing your purchase.